EUVIMEDEUVIMED entdecken
Crossref

LZTFL1 rewires NADPH-glutathione metabolism to amplify ferroptosis

Xiangfei Xue, Xiao Zhang, Qianjun Zhou, Lifang Ma, Yiran Yang, Wanxin Guo, Xin Xu, Yongjie Wang, Jiangtao Cui, Yikun Wang, Shiyu Qiu, Zhixin Yin und 9 weitere

Molecular Cell · 2026

DOI: 10.1016/j.molcel.2026.07.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Cell, 2026. Verfasst von Xiangfei Xue und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Faculty of Medi…. Hauptthemen laut MEDLINE: Ferroptosis, Glutathione, NADP, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Shanghai Chest Hospital, Innovative Research Team of High-level Local University in Shanghai, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferroptosis, a form of oxidative cell death, represents a therapeutic vulnerability for treating apoptosis-resistant cancers. Here, we identify leucine zipper transcription factor-like 1 (LZTFL1) as a key regulator of ferroptosis that rewires glutathione (GSH) metabolism. Mechanistically, LZTFL1 promotes oxidation of glucose-6-phosphate dehydrogenase (G6PD), thereby limiting NADPH production and impairing GSH regeneration. GSH depletion in turn enhances LZTFL1 translation via an AKT-mammalian target of rapamycin (mTOR)-eukaryotic initiation factor 4E (eIF4E) pathway, establishing a feedforward loop that amplifies ferroptosis. In vivo, the LZTFL1-formin homology 2 domain-containing 1 (FHOD1)-G6PD axis sensitizes multiple tumor models, including patient-derived xenografts, to ferroptosis, leading to enhanced lipid peroxidation, reduced GSH levels, suppressed tumor growth, and prolonged survival. LZTFL1 expression restores cisplatin sensitivity in resistant lung and ovarian cancer cells and predicts improved survival outcomes in patients with lung adenocarcinoma. Moreover, FDA-approved agents upregulate LZTFL1 and re-sensitize resistant tumors to cisplatin. These findings highlight LZTFL1 as a potential biomarker and a therapeutic target for enhancing ferroptosis-based cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisGlutathioneNADPLung NeoplasmsTranscription FactorsOvarian NeoplasmsHumansAnimalsCisplatinFemaleDrug Resistance, NeoplasmGlucosephosphate DehydrogenaseCell Line, TumorMiceSignal TransductionXenograft Model Antitumor AssaysAdenocarcinoma of Lung

Stichwörter der Autor:innen

GSH metabolismferroptosislung canceroxidative modification

Substanzen

GlutathioneCisplatinNADPGlucosephosphate DehydrogenaseTranscription FactorsG6PD protein, human

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Faculty of Medical Laboratory Science, College of Health Science and Technology, Shan…
  • Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
  • Department of Surgical Oncology, Shanghai Lung cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
  • Department of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
  • School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Department of Surgery, UT Southwestern Medical Center, Dallas 75390, USA.

Förderung

  • Shanghai Chest Hospital
  • Innovative Research Team of High-level Local University in Shanghai
  • National Natural Science Foundation of China
  • Shanghai Jiao Tong University
  • National Key Research and Development Program of China
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Municipal Education Commission

Zitieren

APA

Xue, X., Zhang, X., Zhou, Q., Ma, L., Yang, Y., Guo, W., Xu, X., Wang, Y., Cui, J., Wang, Y., Qiu, S., Yin, Z., Wang, M., Ling, Y., Yu, Y., Kang, R., Kroemer, G., Qiao, Y., Du, L., …, & Wang, J. (2026). LZTFL1 rewires NADPH-glutathione metabolism to amplify ferroptosis. Molecular Cell. https://doi.org/10.1016/j.molcel.2026.07.018

Vancouver

Xue X, Zhang X, Zhou Q, Ma L, Yang Y, Guo W, et al. LZTFL1 rewires NADPH-glutathione metabolism to amplify ferroptosis. Molecular Cell. 2026. doi:10.1016/j.molcel.2026.07.018

BibTeX
@article{Xue2026,
  author = {Xue, Xiangfei and Zhang, Xiao and Zhou, Qianjun and Ma, Lifang and Yang, Yiran and Guo, Wanxin and Xu, Xin and Wang, Yongjie and Cui, Jiangtao and Wang, Yikun and Qiu, Shiyu and Yin, Zhixin and Wang, Manyuan and Ling, Yuanyuan and Yu, Yongchun and Kang, Rui and Kroemer, Guido and Qiao, Yongxia and Du, Lutao and Tang, Daolin and Wang, Jiayi},
  title = {LZTFL1 rewires NADPH-glutathione metabolism to amplify ferroptosis},
  journal = {Molecular Cell},
  year = {2026},
  doi = {10.1016/j.molcel.2026.07.018}
}
Kostenlos starten →